ReShape Lifesciences ($RSLS) Up 68% Yesterday but Down TodayKey Takeaway
1. ReShape Lifesciences (RSLS) stock rosed on Wednesday on an U.S. Food and Drug Administration (FDA) update.
2. The company got a PMA supplement for its Lap-Band 2.0 FLEX. That news brings with it heavy trading of RSLS shares.
ReShape Lifesciences (NASDAQ:RSLS) stock is rosed higher on Wednesday following approval from the U.S. Food and Drug Administration (FDA) for a PMA supplement. That PMA supplement applies to the company’s Lap-Band 2.0 FLEX. This is the company’s minimally invasive, long-term treatment of obesity.
What This Means for RSLS Stock
Improvement of its weight loss product is a positive for ReShape Lifesciences. The FDA approval also puts its product closer to market, which could mean more revenue for the company.
With this news comes heavy trading of RSLS stock. As of this writing, around 50 million shares have changed hands. That’s a massive leap in trading volume compared to the company’s daily average of about 4 million shares.
Despite the rapid 68% Rapid Surge, NASDAQ:RSLS plummeted in price with the stock trading at 0.3614 (-5.98%) as of the time of writing.
If NASDAQ:RSLS should test the Support level at $0.2990, we should expect a continual trend or a reversal trend.
RSLS
RSLS +500% upside potential according to this analyst RSLS, ReShape Lifesciences, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
On 11/12/2021 Anthony Vendetti from Maxim Group brokerage Reiterated the Buy Rating for RSLS with a price target of $8.00.
That is more that 5X from the current price.
Looking forward to read your opinion about it.
RSLSReShape Lifesciences Inc (NASDAQ:RSLS) looks about ready to pop here! Setting up a possible resistance breakout trade. Technical indicators are supporting a continuation of the recent move higher. The RSI is moving back higher in the bullish zone and the MACD is crossing up. On my fireworks list.
RSLSReShape Lifesciences (NASDAQ:RSLS) had a strong day as the stock closed up 65 cents or 26.21% on heavy volume. Friday’s high of $3.37 is now resistance for the continuation move. The stock is back on top over the 20-day EMA and MACD is showing positive momentum, while KD line also shows buy signal as %K line is on top of %D line.
RSLS Short Term Retracement Still Showing LevelsOnly did the fib retracement back til July because before that the levels are just absurdly higher. So sticking to some level of relevance, we can start to see what areas have materialized as potentially "important" in my opinion. For RSLS , the 786 fib has been a level of high traffic and pivot for the stock. It was previous support back in July and into August, then turned into resistance ever since.
Similar to Kosmos, ReShape hasn’t released much recent news. However, a new VP of Operations and R&D in August along with more substantial revenues for the quarter have been two things traders have focused on. Furthermore, insider buying from CFO Thomas Stankovich this summer came as a vote of confidence for some. Stankovich picked up nearly $50,000 worth of RSLS stock toward the end of August.
However, the company has presented at several industry events and was given a notice of allowance by the US Patent & Trademark Office titled “Intragastric Device” late last month.
RSLS Stock Forecast
According to the World Health Organization, worldwide obesity has nearly tripled since 1975. With an ever-growing population, there remains a constant need for helping those hit by this disease. This week Maxim Group initiated coverage on ReShape with a Buy rating and a price target 167% higher than retail levels on October 8th. Maxim joins other analysts like Alliance Global, who also has a hefty price target on RSLS stock . It sits at $10.25 or roughly 290% higher than where RSLS opened on Friday.
RSLS ReShape Lifesciences Price Target- ReShape leader in weight loss market
- FDA approved Lap-Band manufacturing moved to the US
- eliminated debt overhang
- ReShape Marketplace - digital health solution
June 30, 2021: Cash and cash equivalents and restricted cash were $40.2 million.
ReShape Market Cap only 50.061M
Shares Outstanding 17.20M
On 7/1/2021, Ben Haynor from Alliance Global Partners brokerage Lowered the Price Target from $18.50 to $13.75
My price target is the 9.6usd resistance.
I`m looking forward to read your opinion about RSLS.
RSLS ReShape Lifesciences Global Weight-Loss Leader | $ TargetOn 6/17/2021 Alliance Global Partners brokerage Boosted the Price Target for RSLS ReShape Lifesciences stock from $12.00 to $18.50!
ReShape Lifesciences is America's premier weight-loss solutions company.
The FDA-approved Lap-Band® program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy.
The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. Reshapecare™ virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients, to help them keep the weight off over time. (accesswire.com)
My price target is 12usd short term.